Maze Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of operations and comprehensive income (loss)
(in thousands, except share and per share data)
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| License revenue | $167,500 | $— |
| Operating expenses: | ||
| Research and development | 83,496 | 73,945 |
| General and administrative | 26,418 | 24,606 |
| Total operating expenses | 109,914 | 98,551 |
| Income (loss) from operations | 57,586 | (98,551) |
| Interest and other income, net | 4,654 | 1,966 |
| Change in fair value of convertible promissory notes | (8,837) | (3,830) |
| Income (loss) before income tax expense | $53,403 | $(100,415) |
| Income tax expense | (1,172) | — |
| Net income (loss) and comprehensive income (loss) | $52,231 | $(100,415) |
| Net income (loss) attributable to common stockholders, basic and diluted (see Note 13) | $3,405 | $(100,415) |
| Net income (loss) per share attributable to common stockholders (see Note 13): | ||
| Basic | $1.42 | $(43.89) |
| Diluted | $1.25 | $(43.89) |
| Weighted-average shares used in computing net income (loss) per share attributable to common stockholders (see Note 13): | ||
| Basic | 2,396,094 | 2,287,980 |
| Diluted | 2,730,299 | 2,287,980 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.